Detection method of p-Tau217 protein or fragment thereof, kit and application

Through nanomagnetic microsphere-antibody complex and mass spectrometry detection technology, the detection process of p-Tau 217 protein in Alzheimer's disease is simplified, the complex and expensive detection problems in the existing technology are solved, and efficient and specific Early diagnosis of sex and sensitivity.

CN118896992AActive Publication Date: 2024-11-05NANJING MASS SPECTROMETRY MEDICAL TECH CO LTD +1
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
CN202411207821.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-05
Estimated Expiration
2044-08-30

AI Technical Summary

Technical Problem

The prior art has problems in the early diagnosis of Alzheimer's disease, which are complex, expensive and cannot achieve specific detection. In particular, the detection process of p-Tau 217 protein is complicated and the use of non-specific antibodies leads to large background interference. The need for clinical high throughput and early screening is not met.

Method used

Immunoenrichment using nanomagnetic microsphere-antibody complex, combined with mass spectrometry detection, simplified detection steps, including sample pretreatment, immunoenrichment, cleaning, digestion, desalination and mass spectrometry injection, omitting acid precipitation and solid phase Extraction step, the use of specific antibodies improves the capture efficiency of p-Tau 217.

Benefits of technology

The efficient, sensitivity and precision detection of p-Tau 217 protein is achieved, which reduces sample size requirements, simplifies the operation process, improves the specificity and sensitivity of the detection, and is suitable for early diagnosis and screening of Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118896992A_ABST
    Figure CN118896992A_ABST
Patent Text Reader

Abstract

The invention discloses a detection method and kit for p-Tau 217 protein or fragments thereof and application, and relates to the technical field of protein spectrum detection. The detection method comprises the steps of sample pretreatment, immune enrichment, cleaning, redissolution, digestion and termination, desalination, vacuum concentration, mass spectrum sample introduction and the like. According to the present invention, the specific antibody-microsphere compound and the mass spectrometry detection technology are combined, and the extraction process is optimized so as to solve the problems of complex operation, high consumption, lack of accurate Alzheimer's disease screening ability and the like of the existing Alzheimer's disease detection kit; the method has important application value and significance for large-scale early screening of the Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of protein spectrum detection, and in particular to a detection method, a kit and an application of a p-Tau217 protein or a fragment thereof. Background Art

[0002] Alzheimer's Disease (AD) is a neurodegenerative disease with insidious onset and complex pathology. Its clinical features include irreversible brain damage, cognitive impairment, and decreased ability to take care of oneself in daily life, which can eventually develop into dementia and death. With the aging of the global population, the prevalence and socioeconomic burden of AD continue to increase, which has become one of the major challenges facing global public health. It has developed into the most common dementia and the main cause of increased disability among the elderly worldwide. At present, the clinical diagnosis of AD mainly relies on imaging technology combined with cognitive testing, and the disease is usually diagnosed in the middle and late stages. Although there is no effective treatment for AD, early diagnosis and intervention are still beneficial to reduce neurological damage, delay disease progression, and thus improve the quality of life of patients.

[0003] The pathological characteristics of AD patients are mainly the extracellular deposition of amyloid β (Aβ) in the brain to form senile plaques, and the hyperphosphorylation of Tau protein causes neurofibrillary tangles in brain nerve cells. In the very early stage of AD, the levels of certain protein markers in cerebrospinal fluid (CSF), such as Aβ40, Aβ42, total Tau protein (t-Tau), and hyperphosphorylated Tau protein (p-Tau), will change. However, in order to detect markers in CSF clinically, CSF is often obtained through lumbar puncture. However, this method is an invasive operation, which is very harmful to patients, expensive, and has limited patient acceptance, which is not conducive to the early diagnosis of AD. Studies have found that the blood-brain barrier of AD patients is damaged, which causes certain protein markers in CSF to cross the blood-brain barrier in the early stage of the disease and enter the peripheral blood circulation, thereby causing blood protein marker levels to change significantly in the very early stage of the disease. Therefore, the non-invasive detection technology of AD protein markers in peripheral blood has become the most potential early screening and follow-up method due to its convenient sample collection and low trauma, bringing new hope for the early diagnosis of AD.

[0004] A variety of immunoassay technologies have been applied to the detection of AD blood markers, including single-molecule arrays, electrochemiluminescence, and immunoprecipitation combined with mass spectrometry. Immunoprecipitation-mass spectrometry (IP-MS) is a composite bioanalytical method that combines immunology and mass spectrometry, and is widely used in proteomics research and the identification and quantification of specific proteins or protein complexes in complex biological samples. IP-MS technology first uses specific antibodies to enrich target proteins or protein complexes from complex biological samples through an immunoprecipitation step. Subsequently, the precipitate is analyzed by mass spectrometry (MS) to identify and quantify the target protein. This method combines the high specificity of antibodies with the high sensitivity and high resolution of mass spectrometry, greatly improving the accuracy of quantification and diagnosis.

[0005] Patent CN110869039A provides a method and a kit for measuring the absolute concentration of Tau and other proteins, peptide fragments and protein variants in CSF and plasma samples collected from subjects, which mainly include seven steps: acid precipitation to extract the supernatant, solid phase extraction to remove impurities, non-specific antibody immunoprecipitation, acid elution, enzymatic hydrolysis, desalting, and re-dissolution and reconstruction. The detection process is complicated and time-consuming, and the HJ8.7 antibody used has a weak affinity for p-Tau 217 (peptide sequence: TPSLPTPPTR).

[0006] Nicolas R. Barthe′lemy et al. proposed a method for detecting phosphorylated Tau protein. The detection process is the same as CN110869039A, but the required plasma volume reaches 20 mL, which cannot meet the current situation of limited sample volume in clinical diagnosis.

[0007] Laia Montoliu-Gaya et al. proposed a method for detecting Tau protein in plasma. Although the amount of plasma was reduced to 1 mL, the extraction process still included seven steps: non-specific antibody immunoprecipitation, acid elution, acid precipitation, solid phase extraction, enzymatic hydrolysis, desalting, and re-dissolution and reconstruction. The pre-treatment process was complicated, and the cost of manpower and reagents was high, making it difficult to meet the requirements of clinical high throughput. In addition, the use of non-specific antibodies reduced the extraction effect of phosphorylated p-Tau 217 and increased background interference. In summary, the existing technology has problems such as complicated operating procedures, high costs, and inability to achieve specific detection, and is not suitable for clinical diagnosis. Summary of the invention

[0008] In view of this, the main purpose of the present invention is to provide a detection method, kit and application of p-Tau217 protein or its fragments, in order to at least partially solve the above technical problems.

[0009] In order to achieve the above object, as a first aspect of the present invention, a method for detecting p-Tau 217 protein or a fragment thereof is provided, the method comprising the following steps:

[0010] 1) Sample pretreatment: adding sample diluent to the sample to obtain solution A;

[0011] 2) Immunoenrichment: Add the nanomagnetic microsphere-p-Tau 217 antibody complex to solution A for incubation, and pass through a magnetic rack to obtain a purified immune-enriched complex (i.e., target protein-antibody-nanomagnetic microsphere complex);

[0012] 3) washing: washing the immunoenriched complex with a non-ionic surfactant (e.g., NP40 PBS) to obtain a washed complex;

[0013] 4) adding NH4HCO3 to dissolve the washed complex, and then digesting and terminating;

[0014] 5) Desalting, vacuum concentration and mass spectrometry injection;

[0015] 6) Perform detection using mass spectrometry and output the results.

[0016] Preferably, the sample is a CSF, blood or plasma sample; and / or

[0017] The sample diluent in step 1) includes: Tris-HCl, NaCl, EDTA (ethylenediaminetetraethylene glycol acid), protease inhibitors and phosphatase inhibitors; and / or

[0018] The sample diluent in step 1) further comprises NP40 lysis buffer and / or Tween 20 (polyether sulfate nonionic surfactant); and / or

[0019] The sample diluent in step 1) includes: 20-80mM Tris-HCl, 30-80mM NaCl, 1-10mM EDTA (ethylenediaminetetraethylene glycol acid), and 0.02%-0.2% protease inhibitors and 0.02%-0.2% phosphatase inhibitors by mass fraction; wherein the concentration of Tris-HCl can be 20mM, 25mM, 30mM, 35mM, 40mM, 45mM, 50mM, 55mM, 60mM, 65mM, 70mM, 75mM or all values ​​within the range, which will not be described here due to space limitations. List them one by one; the concentration of NaCl can be 30mM, 35mM, 40mM, 45mM, 50mM, 55mM, 60mM, 65mM, 70mM, 75mM or all values ​​within the range, which will not be listed one by one due to space limitations; the concentration of EDTA can be 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM or all values ​​within the range, which will not be listed one by one due to space limitations. The role of sample diluent: reduce the viscosity of the sample, make the antibody microspheres evenly distributed in the sample, and increase the capture probability of the target protein; create a buffer system and the presence of non-ionic surfactants, which helps the binding of antigens and antibodies and reduces the nonspecific adsorption of microspheres to non-target proteins; since blood contains a series of biologically active enzymes, it can enzymatically hydrolyze proteins in vitro, and the addition of protease inhibitors and phosphatase inhibitors can inhibit the enzymatic hydrolysis of target proteins by biologically active enzymes.

[0020] And / or the sample diluent in step 1) further comprises 0.1%-1% by mass of NP40 and / or Tween 20 (polyether sulfate nonionic surfactant);

[0021] Preferably, step 2) comprises: adding the nanomagnetic microsphere-antibody complex to solution A, incubating with rotation at room temperature for at least 2 hours, and passing through a magnetic rack to obtain a purified immune-enriched complex (i.e., target protein-antibody-nanomagnetic microsphere complex);

[0022] The nanomagnetic microsphere-antibody microsphere complex has a monoclonal antibody for recognizing the p-Tau 217 site, and its purpose is to capture the target protein (p-Tau 217) in plasma to obtain an immune-enriched complex (i.e., the target protein-antibody-nanomagnetic microsphere complex). Nanomagnetic microspheres superparamagnetic microspheres are easy to demagnetize, which is helpful for subsequent separation and efficient washing. Even after multiple magnetizations, the performance of superparamagnetic nanomicrospheres remains unchanged, and the repeatability is good. Since the magnetic frame has a built-in magnet, the magnetic immune-enriched complex (i.e., the target protein-antibody-nanomagnetic microsphere complex) can be fixed on the container wall to achieve separation of the immune-enriched complex, which is conducive to automated conversion. By combining it with specific antibodies, the solution and the nanomagnetic microsphere-antibody microsphere complex can be separated without centrifugation, simplifying the extraction process.

[0023] Preferably, step 3) comprises: washing the immuno-enriched complex at least three times with a PBS solution containing 0.1-0.5% NP40 by mass.

[0024] The role of the nonionic surfactant is to remove the nonspecific adsorption on the surface of the nanomagnetic microsphere-antibody microsphere complex. The mass fraction of the PBS solution of NP40 can be 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45% or all values ​​within the range, which will not be listed one by one due to space limitations.

[0025] Preferably, step 4) comprises: adding 20-200mM NH4HCO3 to dissolve the washed complex, adding trypsin to digest for at least 8h, and adding 10% by mass formic acid aqueous solution to terminate; the main function of ammonium bicarbonate (NH4HCO3) is to provide an alkaline hydrolysis environment to ensure the highest activity of trypsin (optimal pH 8-9), and decompose the p-Tau217 protein into specific peptides that can be used for mass spectrometry detection. The concentration of NH4HCO3 can be 20mM, 30mM, 40mM, 50mM, 60mM, 70mM, 80mM, 90mM, 100mM, 110mM, 120mM, 130mM, 140mM, 150mM, 160mM, 170mM, 180mM, 190mM or all values ​​within the range, which are not listed one by one due to space limitations.

[0026] Preferably, the desalination process in step 5) comprises:

[0027] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0028] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0029] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0030] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0031] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate; and / or

[0032] In the above steps, salt ions will remain, which will not only interfere with mass spectrometry analysis, but also may damage the chromatographic column. Since the stationary phase on the C18 column is composed of silica gel particles modified by octyl (C18) silane compounds with a carbon chain length of 18 carbon atoms, its strong hydrophobicity can effectively retain peptides and remove salt ions in the desalting step.

[0033] The vacuum concentration and mass spectrometry sampling in step 5) includes: passing the desalted sample through a vacuum concentration centrifuge and drying; and / or

[0034] The mass spectrometry sampling process in step 5) includes: re-dissolving the dried sample with a formic acid aqueous solution having a volume fraction of 0.1%, and injecting the sample after oscillation and centrifugation; the mass spectrometer is an orbital ion trap mass spectrometer.

[0035] Preferably, an isotopic peptide segment as shown in Seq No. 1 is added to the reconstituted sample before mass spectrometry injection: TPSLP T PPT R (Among them, the amino acid T at position 6 (see bold and underlined) is phosphorylated, and all C atoms of the amino acid R at position 10 (see bold and underlined) are isotopically labeled. 13 C labeling, all N atoms of amino acid R at position 10 (see bold and underlined) are isotopically 15 N-labeled); and / or before mass spectrometry injection, add the isotope peptide stock solution shown in SeqNo.1 to the reconstituted sample, shake and mix for 1 min, centrifuge for 30 s, and place in the mass spectrometer.

[0036] Preferably, the method comprises the following steps:

[0037] 1) Sample pretreatment: adding a sample diluent to the sample to obtain a solution A; the sample diluent comprises: 0.1%-1% NP40 lysate by mass, 0.1%-1% Tween 20 by mass, 20-80mM Tris-HCl, 30-80mM NaCl, 0.02%-0.2% protease inhibitor by mass, and 0.02%-0.2% phosphatase inhibitor by mass; the sample is a CSF, blood or plasma sample;

[0038] 2) Immunoenrichment: Add the nanomagnetic microsphere-antibody complex to solution A, incubate with rotation at room temperature for at least 2 hours, and pass through a magnetic rack to obtain a purified immune-enriched complex;

[0039] 3) Washing: Wash the immuno-enriched complexes at least three times with a PBS solution containing 0.1-0.5% NP40 by mass to obtain washed complexes;

[0040] 4) Digestion: The washed complex is re-dissolved in 20-200 mM NH4HCO3, and then digested with trypsin for at least 8 h, and terminated by adding 10% by mass formic acid aqueous solution;

[0041] 5) Desalination:

[0042] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0043] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0044] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0045] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0046] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;

[0047] 6) Dry the desalted sample using a vacuum concentrator centrifuge, re-dissolve the dried sample in 0.1% formic acid water, shake and centrifuge, and then inject;

[0048] 7) Detect by mass spectrometry and output the results; before the orbital ion trap mass spectrometer is injected, add the isotope peptide stock solution shown in Seq No. 1 to the reconstituted sample, shake and mix for 1 minute, centrifuge for 30 seconds, place in the mass spectrometer injection system, and perform signal acquisition and signal conversion.

[0049] The principle of the present invention is as follows: the present invention specifically adsorbs the target protein (i.e., p-Tau217 protein or a p-Tau 217 protein fragment that can be specifically recognized by an antibody) in a sample on a nanomagnetic antibody-microsphere complex by means of immune enrichment; since the nanomagnetic microspheres have superparamagnetism, the immune-enriched complex is placed on a magnetic rack with a magnetic field, so that the nanomagnetic antibody-microsphere complex adsorbed with the target protein can be adsorbed, and other impurities that cannot be adsorbed by the immune microspheres cannot remain in the magnetic field, so they can be washed and removed; after thorough washing, the adsorbed antigen-antibody is digested with trypsin to separate them (the antibody is combined with the nanomagnetic microspheres and continues to remain in the magnetic field, while the target protein is released); subsequently, after termination, desalting, drying, centrifugation and other steps, the target protein is thoroughly purified and separated.

[0050] Principle of mass spectrometry detection and internal standard quantification: The target peptide (specific peptide of p-Tau 217 protein) and the stable isotope-labeled peptide have the same physical or chemical properties. Except for slightly different masses, they are fragmented in the same way by collision in the mass spectrometer. Therefore, the signal fluctuations caused by the influence of the matrix during the mass spectrometry detection process can be effectively monitored and corrected. In addition, since the mass spectrometry signal is proportional to the content of the detected object, the content of the target peptide in the sample can be calculated by the signal of the stable isotope-labeled peptide with an accurate content in the mass spectrometer, and the content of the target protein in the sample can be further calculated. Therefore, using the method provided herein, endogenous target proteins and fragments thereof can be quantitatively detected and can be used to diagnose and / or treat subjects suffering from neurological or neurodegenerative diseases or at risk of suffering from neurological or neurodegenerative diseases.

[0051] In a second aspect, the present invention provides a detection kit for p-Tau 217 protein or a fragment thereof, the kit comprising:

[0052] 1) Pretreatment module: at least including a sample diluent, wherein the sample diluent includes: 0.1%-1% NP40 by mass, 0.1%-1% Tween 20 by mass, 20-80mM Tris-HCl, 30-80mM NaCl, 0.02%-0.2% protease inhibitor by mass, and 0.02%-0.2% phosphatase inhibitor by mass;

[0053] 2) Immune enrichment module: at least including nanomagnetic microsphere-antibody complex;

[0054] 3) Cleaning the digestion module: at least a PBS solution containing 0.1% to 0.5% NP40 by mass and a 20-200 mM NH4HCO3 solution;

[0055] 4) Desalination module: at least including methanol, 80% by mass acetonitrile aqueous solution, 1% by mass formic acid aqueous solution, and 80% by mass acetonitrile aqueous solution;

[0056] 5) Drying and injection module: at least including 0.1% by mass formic acid water and the isotopic peptide segment shown in Seq No.1.

[0057] In a third aspect, the present invention provides use of a detection kit for p-Tau 217 protein or a fragment thereof as described in the second aspect in the early diagnosis of Alzheimer's disease.

[0058] Based on the above technical solutions, it can be seen that the detection method, kit and application of p-Tau217 protein or its fragments of the present invention have at least one of the following beneficial effects compared with the prior art:

[0059] The present invention replaces the disclosed TAU broad-spectrum antibody and other technical solutions with a specific antibody-microsphere complex of p-Tau 217 protein, specifically captures p-Tau 217, improves the enrichment and detection efficiency of p-Tau 217, and designs a new experimental scheme on this basis, reduces the steps of acid precipitation, solid phase extraction and other steps to reduce the loss during the operation. Furthermore, combined with mass spectrometry detection technology, the detection accuracy is guaranteed. The detection method of phosphorylated p-Tau 217 protein or its fragment provided by the present invention has simple steps, short detection time, high sensitivity, good precision, high credibility of the detection result, and only 5 steps are required to complete the mass spectrometry detection pretreatment, and the required sample amount is reduced by about 75%, wherein the cleaning step is simplified, and the acid precipitation, acid cleaning and solid phase extraction steps in the prior art are omitted; and the digestion and incubation time is greatly shortened. It solves the problems of the existing Alzheimer's disease detection kit being complicated to operate, expensive, and lacking the ability to accurately screen Alzheimer's disease, and has important application value and significance for the large-scale early screening of Alzheimer's disease.

[0060] The present invention can be used for the analysis and detection of early diagnostic markers for Alzheimer's disease, effectively improving the capture efficiency of p-Tau 217, and improving the specificity and sensitivity of early diagnosis and screening of Alzheimer's disease. Then, through the optimization of reagents and test steps, a unique buffer system is used to improve the stability of reagents and the repeatability of detection, and five major steps including sample pretreatment, immunoprecipitation, enzymatic hydrolysis, desalting, and re-dissolution and reconstruction are implemented, simplifying the detection process and time. In short, the analytical detection method of the present invention has higher detection sensitivity, specificity, and stability, and has important application value and significance for large-scale early screening of Alzheimer's disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1is the p-Tau217 protein calibration curve of Example 1;

[0062] Figure 2 1 is the quantitative limit chromatogram of p-Tau217 in Example 1; 1 is the isotope peptide chromatogram; 2 is the target protein peptide chromatogram in Example 1;

[0063] Figure 3 is the p-Tau217 protein calibration curve of Example 2;

[0064] Figure 4 is the p-Tau217 protein calibration curve of Example 3;

[0065] Figure 5 is the p-Tau217 protein calibration curve of Example 4;

[0066] Figure 6 This is a comparison diagram of the immunoenrichment of p-Tau217 in plasma samples by the p-Tau217 specific antibody and the Tau antibody in Comparative Example 2;

[0067] Figure 7 It is a peak area comparison chart of p-Tau217 protein in plasma samples extracted according to the processing steps of Example 1 (20240712_A_B01), Comparative Example 2 (20240712_B_B01), and Comparative Example 3 (20240712_C_B01);

[0068] Figure 8 This is the p-Tau217 protein calibration curve of Comparative Example 4. DETAILED DESCRIPTION

[0069] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings.

[0070] Collection of plasma samples: Peripheral blood from Alzheimer's patients and healthy subjects was collected from the blood bank of a municipal hospital in Anhui Province. After plasma was extracted from each peripheral blood sample, it was stored at -80℃ for future use.

[0071] The important reagents used in the specific embodiments of the present invention are shown in Table 1. The mass spectrometer was Exploris 480 (Thermofisher scientific), and the instrument parameters were as follows: Isolation window: 0.7; HCD: 30%; Orbitrap Resolution: 45000; Scan range: 120-1500; RFlens: 50%; AGC: 100%; Maximun injection Time: 110; Chromatographic analysis time: 30 min; Injection volume: 4 μL.

[0072] Table 1 Reagents used in the specific embodiments of the present invention

[0073]

[0074] The prior art mass spectrometry detection of markers of Alzheimer's disease has cumbersome pre-processing steps, complex operating procedures, long time consumption, and low sensitivity. After careful research, the inventors of the present invention have simplified and optimized the above steps, so that a higher detection accuracy and detection limit can be achieved through simpler operations. Specifically, the present invention discloses a method for detecting p-Tau 217 protein or a fragment thereof, the method comprising the following steps:

[0075] 1) Sample pretreatment: adding sample diluent to the sample to obtain solution A;

[0076] 2) Immunoenrichment: Add the nanomagnetic microsphere-antibody complex to solution A, incubate with rotation at room temperature, and pass through a magnetic rack to obtain a purified immune-enriched complex;

[0077] 3) washing: washing the immuno-enriched complex with a non-ionic surfactant to obtain a washed complex;

[0078] 4) adding NH4HCO3 to dissolve the washed complex, and then digesting and terminating;

[0079] 5) Desalting, vacuum concentration and mass spectrometry injection;

[0080] 6) Perform detection using mass spectrometry and output the results.

[0081] In a preferred embodiment, the sample is a CSF, blood or plasma sample; and / or

[0082] The sample diluent in step 1) includes: Tris-HCl, NaCl, EDTA (ethylenediaminetetraethylene glycol acid, protease inhibitors and phosphatase inhibitors; and / or

[0083] The sample diluent in step 1) further comprises NP40 lysis buffer and / or Tween 20 (polyether sulfate nonionic surfactant); and / or

[0084] The sample diluent in step 1) includes: 20-80 mM Tris-HCl, 30-80 mM NaCl, 1-10 mM EDTA (ethylenediaminetetraethylene glycol acid), and 0.02%-0.2% protease inhibitor and 0.02%-0.2% phosphatase inhibitor by mass fraction;

[0085] And / or the sample diluent in step 1) further comprises 0.1%-1% by mass of NP40 and / or Tween 20 (polyether sulfate nonionic surfactant);

[0086] In a preferred embodiment, step 2) comprises: adding the nanomagnetic antibody microsphere complex to solution A and incubating with rotation at room temperature for at least 2 hours;

[0087] In a preferred embodiment, step 3) comprises: washing the immuno-enriched complex at least three times with a PBS solution containing 0.1-0.5% NP40 by mass.

[0088] In a preferred embodiment, step 4) comprises: adding 20-200 mM NH4HCO3 to dissolve the washed complex, then adding trypsin to digest for at least 8 hours, and adding 10% by mass formic acid aqueous solution to terminate the digestion;

[0089] In a preferred embodiment, the desalination process in step 5) comprises:

[0090] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0091] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0092] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0093] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0094] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate; and / or

[0095] The vacuum concentration and mass spectrometry sampling in step 5) includes: passing the desalted sample through a vacuum concentration centrifuge and drying; and / or

[0096] The mass spectrometry sampling in step 5) includes: re-dissolving the dried sample with a 0.1% by mass formic acid aqueous solution, and injecting the sample after oscillation and centrifugation; the mass spectrometry is an orbital ion trap mass spectrometry;

[0097] In a preferred embodiment, in step 5), the isotope peptide segment shown in Seq No. 1 is added during mass spectrometry injection and / or the isotope peptide segment stock solution shown in Seq No. 1 is added to the reconstituted sample before mass spectrometry injection, the mixture is shaken and mixed for 1 min, centrifuged for 30 s, and placed in the mass spectrometer.

[0098] In a preferred embodiment, the method comprises the following steps:

[0099] 1) Sample pretreatment: adding a sample diluent to the sample to obtain a solution A; the sample diluent comprises: 0.1%-1% NP40 lysate, Tween 20, 20-80mM Tris-HCl, 30-80mM NaCl, 0.02%-0.2% protease inhibitor, and 0.02%-0.2% phosphatase inhibitor; the sample is a CSF, blood or plasma sample;

[0100] 2) Immunoenrichment: Add the nanomagnetic microsphere-antibody complex to solution A, incubate with rotation at room temperature for at least 2 hours, and pass through a magnetic rack to obtain a purified immune-enriched complex;

[0101] 3) Washing: Wash the immuno-enriched complexes at least three times with a PBS solution containing 0.1-0.5% NP40 by mass to obtain washed complexes;

[0102] 4) Digestion: The washed complex is re-dissolved in 20-200 mM NH4HCO3, and then digested with trypsin for at least 8 h, and terminated by adding 10% by mass formic acid aqueous solution;

[0103] 5) Desalination:

[0104] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0105] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0106] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0107] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0108] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;

[0109] 6) Dry the desalted sample using a vacuum concentrator centrifuge, re-dissolve the dried sample in 0.1% formic acid water, shake and centrifuge, and then inject;

[0110] 7) Detect with mass spectrometry and output the results; add the isotope peptide segment shown in SeqNo.1 when injecting the orbital ion trap mass spectrometer: TPSLP T PPT R (Among them, the amino acid T at position 6 (see bold and underlined) is phosphorylated, and all C atoms of the amino acid R at position 10 (see bold and underlined) are isotopically labeled. 13 C labeling, all N atoms of amino acid R at position 10 (see bold and underlined) are isotopically 15 N mark).

[0111] The principle of the present invention is as follows: the present invention specifically adsorbs the target protein (i.e., p-Tau217 protein or a p-Tau 217 protein fragment that can be specifically recognized by an antibody) in the sample by immunoenrichment; since the nanomagnetic microspheres have superparamagnetism, the immunoenriched complex is placed on a magnetic frame with a magnetic field, and the nanomagnetic microsphere-antibody complex adsorbed with the target protein can be adsorbed, and other impurities that cannot be adsorbed by the immune microspheres cannot remain in the magnetic field, so they can be washed and removed; after thorough washing, the adsorbed antigen-antibody is digested with trypsin to separate them (the antibody binds to the nanomagnetic microspheres and continues to remain in the magnetic field, while the target protein is released); subsequently, after termination, desalting, drying, centrifugation and other steps, the target protein is thoroughly purified and separated. Principle of mass spectrometry detection: The target peptide (specific peptide of p-Tau 217 protein) and the stable isotope labeled peptide have the same physical or chemical properties, except for slightly different masses, and they are fragmented in the same way by collision in the mass spectrum. Therefore, the signal fluctuation caused by the influence of the matrix during the mass spectrometry detection process can be effectively monitored and corrected. In addition, since the mass spectrometry signal is proportional to the content of the detected object, the content of the target peptide segment in the sample can be calculated by the signal of the stable isotope-labeled peptide segment with accurate content in the mass spectrometry, and the content of the target protein in the sample can be further calculated. Therefore, using the technology provided herein, endogenous target proteins and their fragments can be quantitatively detected and can be used to diagnose and / or treat subjects suffering from neurological or neurodegenerative diseases or at risk of suffering from neurological or neurodegenerative diseases.

[0112] In a second aspect, the present invention provides a detection kit for p-Tau 217 protein or a fragment thereof, the kit comprising:

[0113] 1) Pretreatment module: at least including a sample diluent, wherein the sample diluent includes: NP40 lysate with a mass fraction of 0.1%-1%, Tween 20 with a mass fraction of 0.1%-1%, Tris-HCl with a concentration of 20-80mM, NaCl with a concentration of 30-80mM, protease inhibitor with a mass fraction of 0.02%-0.2%, and phosphatase inhibitor with a mass fraction of 0.02%-0.2%;

[0114] 2) Immune enrichment module: at least including nanomagnetic antibody microsphere complex;

[0115] 3) Cleaning and re-dissolving module: at least including PBS solution with a mass fraction of 0.1-0.5% NP40 and NH4HCO3 solution with a concentration of 20-200mM;

[0116] 4) Desalination module: at least including methanol, 80% by mass acetonitrile aqueous solution, 1% by mass formic acid aqueous solution, and 80% by mass acetonitrile aqueous solution;

[0117] 5) Drying and injection module: at least including 0.1% by mass formic acid water and the isotopic peptide segment shown in Seq No.1.

[0118] In a third aspect, the present invention provides use of a detection kit for p-Tau 217 protein or a fragment thereof as described in the second aspect in the early diagnosis of Alzheimer's disease.

[0119] In a preferred embodiment, the detailed preparation method of the nanomagnetic microsphere-p-Tau217 protein antibody complex used in the present invention is as follows:

[0120] The nanomagnetic microsphere suspension was placed in a 1.5 mL EP tube and washed with 2 mM EDTA in PBS solution for 3 times by rotation, 3 min / time, 1 mL / time. After removing the supernatant, p-Tau 217 antibody and 500 μL PBS solution were added, and the mixture was incubated at 4 °C for 8 h to obtain a nanomagnetic antibody microsphere-p-Tau 217 antibody complex.

[0121] The present invention will be further described below through specific examples. It should be noted that the following examples are only for illustration and are not intended to limit the present invention.

[0122] Example 1

[0123] (I) Reagent preparation:

[0124] (1) Preparation of sample diluent: 0.2 mL NP40, 2 mL 1 mM Tris-HCl, 0.14 g NaCl, 58.5 mg EDTA, 40 μL protease inhibitor, 40 μL phosphatase inhibitor and 37.8 mL water were mixed to prepare sample diluent;

[0125] (2) Preparation of cleaning solution: Mix 0.05 mL NP40 with 100 mL PBS to obtain a 0.5% NP40 PBS solution;

[0126] (3) Preparation of digestion solution: Mix 197.64 mg of NH4CHO3 with 50 mL of purified water to obtain 50 mM NH4CHO3;

[0127] (4) Preparation of trypsin solution: Mix 20 μg of trypsin with 1 mL of 0.1% (v / v) formic acid water;

[0128] (5) Preparation of reconstitution solution: 50 pg of TPSLPpTPPTR ( 13 C6 15 N2) was mixed with 1 mL of 0.1% (v / v) formic acid in water.

[0129] (II) Steps:

[0130] 1) Sample pretreatment: Add sample diluent to 0.25-1 mL of sample at a ratio of 1:2, rotate and mix to obtain solution A;

[0131] 2) Immunoenrichment: The nanomagnetic microsphere-antibody complex was added to solution A successively, and incubated with rotation at room temperature for 2 hours to obtain an immunoenriched complex, i.e., a protein-antibody-microsphere complex;

[0132] 3) Washing: The protein-antibody-microsphere complex in 2) was placed on a magnetic stand for 1 min. After solid-liquid separation, the supernatant was removed, and 0.5% NP40 PBS was added. The mixture was washed by rotation at 1 ml / time and 5 min / time. The operation was repeated 3 times to obtain a washed complex.

[0133] 4) Digestion: Add 1 mL of 50 mM NH4HCO3 solution to the complex washed in 3), and wash by rotation for 5 min / time. Repeat the operation 3 times, replace the solvent, add 1 μL of 20 μg / ml trypsin, oscillate for 30 s, sonicate for 30 s, place on a constant temperature oscillator, digest at 37°C and 1000 rpm for 12 hours, and then add 10% formic acid solution and vortex oscillate for 5 min to terminate the digestion;

[0134] 5) Desalination:

[0135] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0136] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0137] ③ Add 200 μL 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0138] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0139] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;

[0140] 6) Place in a vacuum freeze dryer and spin centrifuge for 30 minutes to remove the solvent.

[0141] 7) Before mass spectrometry injection, add 10 μL of the reconstitution solution, oscillate and mix for 5 minutes, and centrifuge for 30 seconds to prepare for mass spectrometry detection; then perform mass spectrometry detection.

[0142] (1) Linearity verification: Recombinant phosphorylated Tau protein with final concentrations of 0.1 pg / mL, 1 pg / mL, 5 pg / mL and 30 pg / mL was added to 1 mL of blank plasma to prepare a calibration curve, and the sample was processed and tested according to the sample processing process of Example 1. The ratio of the signal intensity of the peptide segment corresponding to the target protein to the signal intensity of the isotope peptide segment (peak area ratio) was used as the ordinate, and the concentration of the target protein was used as the abscissa for linear fitting. Figure 1 The calibration curve shown in the figure shows that the linear correlation coefficient R 2 =0.9985, indicating that the target protein of Example 1 has good linearity in the concentration range of 0.1-30 pg / ml. The chromatogram of p-Tau 217 at the quantitative limit (0.1 pg / mL) is shown in Figure 2 As shown in the figure, the target peptide and isotopic peptide are completely separated from the baseline, meeting the quantitative requirements.

[0143] (2) Precision determination: Actual samples of different age groups (whose target proteins are known to differ) were tested separately, and the samples were processed three times in parallel according to the processing procedure of Example 1. The peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample. The results are shown in Table 2. It can be seen that the precision CV of the determination results in Example 1 was <15%.

[0144] Table 2 Precision measurement results of Example 1

[0145]

[0146] (3) Accuracy determination: Recombinant phosphorylated Tau protein with a final concentration of 0.15 pg / mL and 0.8 pg / mL was added to the plasma, and the treatment and detection were carried out according to the treatment process of Example 1, and the peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample, according to accuracy = (test result after addition - background concentration) / theoretical concentration * 100%. The results are shown in Table 3, and it can be seen that the accuracy of Example 1 is >85%.

[0147] Table 3 Accuracy test of Example 1

[0148] serial number Sample 1 Sample 2 Test results after spike 0.130 0.683 Background concentration 0.15 0.80 Accuracy, % 86.66 85.38

[0149] Example 2

[0150] The difference between Example 2 and Example 1 is that the sample diluent is composed of 0.5% Tween-20, 50 mM Tris-HCl, 60 mM NaCl and 5 mM EDTA (ethylenediaminetetraethylene glycol acid); other reagent compositions and experimental steps are the same.

[0151] (1) Linearity verification: Recombinant phosphorylated Tau protein with final concentrations of 0.1 pg / mL, 1 pg / mL, 5 pg / mL and 30 pg / mL was added to 1 mL of blank plasma to prepare a calibration curve, and the sample was processed and tested according to the sample processing process of Example 2. The ratio of the signal intensity of the peptide segment corresponding to the target protein to the signal intensity of the isotope peptide segment (peak area ratio) was used as the ordinate, and the concentration of the target protein was used as the abscissa for linear fitting. Figure 3 The calibration curve shown in the figure shows that the linear correlation coefficient R 2 =0.9946, indicating that the target protein has good linearity in the concentration range of 0.1-30 pg / mL.

[0152] (2) Precision determination: Actual samples of different age groups (whose target proteins are known to differ) were tested separately, and the samples were processed three times in parallel according to the processing procedure of Example 2. The peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample. The results are shown in Table 4. It can be seen that the precision CV of the determination results in Example 2 was <15%.

[0153] Table 4 Precision measurement results of Example 2

[0154] Group Sample 1 Sample 2 1 0.091 0.032 2 0.082 0.030 3 0.091 0.029 Mean 0.09 0.03 CV, % 5.90 5.04

[0155] (3) Accuracy determination: Recombinant phosphorylated Tau protein with a final concentration of 0.15 pg / mL and 0.8 pg / mL was added to the plasma, and the treatment and detection were performed according to the operating steps of the kit of the present invention, and the peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample, according to accuracy = (test result after addition - background concentration) / theoretical concentration * 100%. The results are shown in Table 5, and it can be seen that the accuracy of Example 2 is >80%.

[0156] Table 5 Accuracy measurement results of Example 2

[0157] serial number Sample 1 Sample 2 Test results after spike 0.157 0.731 Background concentration 0.032 0.057 Accuracy, % 83.33 84.25

[0158] Example 3

[0159] The difference between this embodiment and embodiment 1 is that the sample diluent is composed of 0.5% Tween-20, 50 mM Tris-HCl, 80 mM NaCl and 5 mM EDTA (ethylenediaminetetraethylene glycol acid). The other reagent compositions and experimental steps are the same.

[0160] (1) Linearity verification: Recombinant phosphorylated Tau protein with final concentrations of 0.1 pg / mL, 1 pg / mL, 5 pg / mL and 30 pg / mL was added to 1 mL of blank plasma to prepare a calibration curve, and the sample was processed and tested according to the sample processing process of Example 3. The ratio of the signal intensity of the peptide segment corresponding to the target protein to the signal intensity of the isotope peptide segment (peak area ratio) was used as the ordinate, and the concentration of the target protein was used as the abscissa for linear fitting. Figure 4 The calibration curve shown in the figure shows that the linear correlation coefficient R 2 =0.9989, indicating that the target protein has good linearity in the concentration range of 0.1 to 30 pg / ml.

[0161] (2) Precision test: Actual samples of different age groups (whose target proteins are known to differ) were tested separately, and the samples were processed three times in parallel according to the processing procedure of Example 3. The peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample. The results are shown in Table 4. It can be seen that the precision CV of the measurement results in Example 3 is <15%.

[0162] Table 6 Precision test results of Example 3

[0163] Group Sample 1 Sample 2 1 0.208 0.049 2 0.221 0.053 3 0.191 0.051 Mean 0.21 0.05 CV, % 7.28 9.25

[0164] (3) Accuracy determination: Recombinant phosphorylated Tau protein with a final concentration of 0.15 pg / mL and 0.8 pg / mL was added to the plasma, and the treatment and detection were performed according to the operating steps of the kit of the present invention, and the peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample, according to accuracy = (test result after addition - background concentration) / theoretical concentration * 100%. The results are shown in Table 7, and it can be seen that the accuracy of Example 3 is >80%.

[0165] Table 7 Accuracy test results of Example 3

[0166] serial number Sample 1 Sample 2 Test results after spike 0.166 0.733 Background concentration 0.037 0.068 Accuracy, % 86.00 83.13

[0167] Example 4

[0168] The difference between Example 4 and Example 1 is that the cleaning ratio is 0.1% NP40 PBS solution. The other reagent compositions and experimental steps are the same.

[0169] (1) Linearity verification: Recombinant phosphorylated Tau protein with final concentrations of 0.1 pg / mL, 1 pg / mL, 5 pg / mL and 30 pg / mL was added to 1 mL of blank plasma to prepare a calibration curve, and the sample processing and detection were performed according to the sample processing process of Example 4. The ratio of the signal intensity of the peptide segment corresponding to the target protein to the signal intensity of the isotope peptide segment (peak area ratio) was used as the ordinate, and the concentration of the target protein was used as the abscissa to perform a linear fit. Figure 5 The calibration curve shown in the figure shows that the linear correlation coefficient R 2 =0.9998, indicating that the target protein has good linearity in the concentration range of 0.1 to 30 pg / ml.

[0170] (2) Precision test: Actual samples of different age groups (whose target proteins are known to differ) were tested separately, and the samples were processed three times in parallel according to the processing procedure of Example 4. The peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample. The results are shown in Table 8. It can be seen that the precision CV of the measurement results in Example 4 was <15%.

[0171] Table 8 Precision test results of Example 4

[0172]

[0173]

[0174] (3) Accuracy determination: Recombinant phosphorylated Tau protein with a final concentration of 0.15 pg / mL and 0.8 pg / mL was added to the plasma, and the treatment and detection were performed according to the operating steps of the kit of the present invention, and the peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample, according to accuracy = (test result after addition - background concentration) / theoretical concentration * 100%. The results are shown in Table 9, and it can be seen that the accuracy of Example 4 is >80%.

[0175] Table 9 Accuracy test results of Example 4

[0176] serial number Sample 1 Sample 2 Test results after spike 0.29 0.82 Background concentration 0.163 0.15 Accuracy, % 84.67 83.75

[0177] Example 5

[0178] The difference between Example 5 and Example 1 is that the concentration of Tris-HCl in the sample diluent is set to 20, 40, 60, and 80 mM. The other reagent compositions and experimental steps are the same. The performance indicators such as linearity, precision, and accuracy are verified. The verification results are shown in Table 10, where the linear correlation coefficient (R 2 ) were all greater than 0.992, precision (CV) <10%, and accuracy >85%.

[0179] Table 10 Statistical table of performance index verification results of Example 5

[0180] Tris-HCl concentration 20mM 40mM 60mM 80mM <![CDATA[Linear verification (R 2 )]]> 0.9972 0.9921 0.9977 0.9968 Precision (CV,%) 2.88 3.56 7.16 9.14 Accuracy (%) 85.10 87.31 90.17 98.60

[0181] Example 6

[0182] The difference between Example 6 and Example 1 is that the concentration of NaCl in the sample diluent is set to 30, 50, 70, and 80 mM. The other reagent compositions and experimental steps are the same. The linearity, precision, and accuracy performance indicators are verified. The results are shown in Table 11, where the linear correlation coefficient (R 2 ) were all greater than 0.993, precision (CV) <11%, and accuracy >85%.

[0183] Table 11 Statistical table of performance index verification results of Example 6

[0184]

[0185] Example 7

[0186] The difference between Example 7 and Example 1 is that the concentration of EDTA in the sample diluent is set to 2, 4, 6, 8, and 10 mM. The other reagent compositions and experimental steps are the same. The linearity, precision, and accuracy performance indicators are verified. The results are shown in Table 12, where the linear correlation coefficient (R 2) were all greater than 0.991, precision (CV) <11%, and accuracy >80%.

[0187] Table 12 Statistical table of performance index verification results of Example 7

[0188]

[0189] Example 8

[0190] The difference between Example 8 and Example 1 is that the concentration of NP40 in the cleaning solution is set to 0.2, 0.4, 0.6, and 0.8%. The other reagent compositions and experimental steps are the same. The linearity, precision, and accuracy performance indicators are verified. The results are shown in Table 13, where the linear correlation coefficient (R 2 ) were all greater than 0.995, precision (CV) <11%, and accuracy >80%.

[0191] Table 13 Statistical table of performance index verification results of Example 8

[0192]

[0193]

[0194] Example 9

[0195] The difference between Example 9 and Example 1 is that the concentration of NH4HCO3 in the digestive fluid is set to 20, 45, 90, and 180 mM. The other reagent compositions and experimental steps are the same. The linearity, precision, and accuracy performance indicators are verified. The results are shown in Table 14, where the linear correlation coefficient (R 2 ) were all greater than 0.995, precision (CV) <10%, and accuracy >80%.

[0196] Table 14 Statistical table of performance index verification results of Example 9

[0197]

[0198] Comparative Example 1

[0199] The difference between Comparative Example 1 and Example 1 is that Tau antibody-nanomagnetic microsphere complex is used. The other reagent compositions and experimental steps are the same. The positive plasma samples from the same source are processed and mass spectrometrically detected. Figure 6 As shown, it can be seen that the enrichment effect of the p-Tau217 antibody-nanomagnetic microsphere antibody complex is significantly better than that of the Tau-nanomagnetic microsphere antibody complex, and its p-Tau217 detection concentration is about 1.5 times.

[0200] Comparative Example 2

[0201] 1) Immunoenrichment: After thawing 1 mL of plasma, vortex at 2000 rpm for 30 seconds and centrifuge at 4000 g for 10 minutes. 50 μL of Tau antibody-microsphere complex was added to the plasma and incubated at room temperature for 2 hours to obtain the immunoenriched complex, i.e., protein-antibody-microsphere complex;

[0202] 3) Washing: Wash with 1 mL PBS, 0.05% NP40 PBS, and 50 mM ammonium bicarbonate, respectively, at a rate of 1 mL / time, 5 min / time, and perform rotation washing. Repeat the operation 3 times to obtain a washed complex.

[0203] 4) Acid elution and acid precipitation: add 1 mL of 0.5% formic acid solution for 5 min / time and rotate and incubate. Take the supernatant and add 15 μL of 60% perchloric acid solution. Vortex and shake for 30 s. Ice bath for 30 min. Centrifuge at 3000 g for 30 min.

[0204] 5) Solid phase extraction: Take 3mg Oasis PRiME HLB SPE plate, add 200μL methanol and 200μL 0.1% perchloric acid to activate the balance, transfer all the solution in 4) to the SPE plate, elute with 2*200μL 5% methanol water, and finally elute with 200μL 50% acetonitrile water containing 0.1% trifluoroacetic acid. Then vacuum freeze-dry for 1h;

[0205] 6) Digestion: 40 μL 2.5 ug / ml pancreatin was vortexed for 30 seconds, ultrasonicated for 30 seconds, placed on a constant temperature oscillator, and digested at 37 degrees and 1000 rpm for 18 hours, and then 10% trifluoroacetic acid solution was added and vortexed for 5 minutes to terminate the digestion;

[0206] 7) Desalination:

[0207] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0208] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0209] ③ Add 200 μL 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0210] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0211] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;

[0212] 8) Place the mixture in a vacuum freeze dryer and spin centrifuge for 30 min to remove the solvent.

[0213] 9) Before mass spectrometry injection, add 50 μL of 0.01% trifluoroacetic acid, shake and mix for 5 minutes, and centrifuge for 30 seconds to prepare for mass spectrometry detection.

[0214] The positive plasma samples from the same source were processed and mass spectrometrically detected according to the steps of Comparative Example 2 and Example 1. Figure 6 As shown, the detected concentration of p-Tau 217 is much lower than that of Example 1, which is about 35% of that of Example 1. Since the processing steps of this comparative example are more complicated, there is a large loss in the processing process.

[0215] Comparative Example 3

[0216] 1) Immunoenrichment: 1 mL of plasma was thawed, vortexed at 2000 rpm for 30 s, and centrifuged at 4000 g for 10 min;

[0217] 2) Acid precipitation: add 58.48 μL of 65% perchloric acid solution to the centrifuged plasma, vortex for 30 seconds, ice bath for 30 minutes, centrifuge at 16000g for 30 minutes, and then add trifluoroacetic acid to 1%;

[0218] 3) Solid phase extraction: Take 3mg Oasis PRiME HLB SPE plate, add 200μL methanol and 200μL 0.1% (v / v) trifluoroacetic acid to activate the balance, transfer all the solutions in 2) to the SPE plate, elute with 2*200μL 0.1% (v / v) trifluoroacetic acid, and finally elute with 700μL 27.5% acetonitrile water containing 0.1% (v / v) trifluoroacetic acid. Then vacuum freeze-dry for 1h, re-dissolve with 1mL sample diluent, and vortex mix for 1min;

[0219] 4) Immunoenrichment: Add 50 μL of Tau antibody-microsphere complex to the solution in 3), and incubate with rotation at room temperature for 2 h to obtain an immunoenriched complex, i.e., a protein-antibody-microsphere complex;

[0220] 5) Washing: Wash with 1 ml PBS, 0.05% NP40 PBS, and 50 mM ammonium bicarbonate, respectively, at a rate of 1 ml / time, 5 min / time, and perform rotation washing. Repeat the operation 3 times to obtain a washed complex.

[0221] 6) Digestion: 40 μL 2.5 ug / ml pancreatin was vortexed for 30 seconds, ultrasonicated for 30 seconds, placed on a constant temperature oscillator, and digested at 37 degrees and 1000 rpm for 18 hours, and then 10% trifluoroacetic acid solution was added and vortexed for 5 minutes to terminate the digestion;

[0222] 7) Desalination:

[0223] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0224] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0225] ③ Add 200 μL 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0226] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0227] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;

[0228] 8) Place the mixture in a vacuum freeze dryer and spin centrifuge for 30 min to remove the solvent.

[0229] 9) Before mass spectrometry injection, add 25 μL of 0.01% trifluoroacetic acid, shake and mix for 5 minutes, and centrifuge for 30 seconds to prepare for mass spectrometry detection.

[0230] According to the steps of Comparative Example 2 and Example 1, the positive plasma samples from the same source were processed and mass spectrometrically detected. The detection results of p-Tau217 in Comparative Example 3 were compared with Figure 7 As shown. It can be seen that the detection concentration of p-Tau 217 is much lower than that of Example 1, which is about 25% of that of Example 1. At the same time, the steps of acid elution, acid precipitation, solid phase extraction, etc. are added on the basis of Example 1. The results show that the extraction effect of p-Tau 217 in Comparative Example 3 is not good.

[0231] Comparative Example 4

[0232] The difference between Comparative Example 4 and Example 1 is that before mass spectrometry injection, no TPSLPpTPPTR ( 13 C6 15 N2) isotope peptides were used to verify the linearity, precision and accuracy performance indicators.

[0233] (1) Linearity verification: Recombinant phosphorylated Tau protein with final concentrations of 0.1 pg / mL, 1 pg / mL, 5 pg / mL and 30 pg / mL was added to 1 mL of blank plasma to prepare a calibration curve, and the sample processing and detection were performed according to the sample processing process of Example 4. The ratio of the signal intensity of the peptide segment corresponding to the target protein to the signal intensity of the isotope peptide segment (peak area ratio) was used as the ordinate, and the concentration of the target protein was used as the abscissa to perform a linear fit. Figure 8 The calibration curve shown in the figure shows that the linear correlation coefficient R 2=0.9674, indicating that without isotope peptide signal correction, the linearity of p-Tau217 in the concentration range of 0.1 to 30 pg / ml is poor.

[0234] (2) Precision test: Actual samples of different age groups (whose target proteins are known to differ) were tested separately, and the samples were processed three times in parallel according to the processing procedure of Comparative Example 4. The peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual samples. The results are shown in Table 8. It can be seen that the precision of the low-concentration samples in the determination results of Comparative Example 4 is 19.14%, which is greater than 15%.

[0235] Table 15 Precision test results of comparative example 4

[0236] Group Sample 1 Sample 2 1 0.97 0.11 2 1.13 0.089 3 0.86 0.086 Mean 0.99 0.10 CV, % 13.76 19.14

[0237] (3) Accuracy determination: Recombinant phosphorylated Tau protein with a final concentration of 0.15 pg / mL and 0.8 pg / mL was added to the plasma, and the treatment and detection were carried out according to the operating steps of the kit of the present invention, and the peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample, according to accuracy = (test result after addition - background concentration) / theoretical concentration * 100%. The results are shown in Table 16, and it can be seen that the accuracy of Comparative Example 4 is <80%.

[0238] Table 16 Accuracy test results of comparative example 4

[0239]

[0240]

[0241] In summary, the detection method of phosphorylated p-Tau 217 protein or its fragment provided by the present invention has simple steps, short detection time, high sensitivity, good precision, high credibility of detection results, and only 5 steps are needed to complete the mass spectrometry detection pretreatment, and the required sample volume is reduced by about 75%, wherein the cleaning step is simplified, and the acid precipitation, acid cleaning and solid phase extraction steps in the prior art are omitted. In addition, the digestion and incubation time is greatly shortened. The present invention combines the specific antibody-microsphere complex of p-Tau 217 protein with mass spectrometry detection technology, optimizes the extraction process, solves the problems of the existing Alzheimer's disease detection kit being complicated to operate, expensive, and lacking the ability to accurately screen Alzheimer's disease, and has important application value and significance for the large-scale early screening of Alzheimer's disease.

[0242] The present invention can be used for the analysis and detection of early diagnostic markers for Alzheimer's disease, effectively improving the capture efficiency of p-Tau 217, and improving the specificity and sensitivity of early diagnosis and screening of Alzheimer's disease. Then, through the optimization of reagents and test steps, a unique buffer system is used to improve the stability of reagents and the repeatability of detection, and five major steps including sample pretreatment, immunoprecipitation, enzymatic hydrolysis, desalting, and re-dissolution and reconstruction are implemented, simplifying the detection process and time. In short, the analytical detection method of the present invention has higher detection sensitivity, specificity, and stability, and has important application value and significance for large-scale early screening of Alzheimer's disease.

[0243] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A method for detecting p-Tau 217 protein or a fragment thereof, characterized in that: The following steps are involved: 1) Sample pretreatment: adding sample diluent to the sample to obtain solution A; 2) Immunoenrichment: Add the nanomagnetic microsphere-p-Tau 217 antibody complex to solution A for incubation, and obtain the purified immune-enriched complex after passing through a magnetic rack; 3) washing: washing the immune-enriched complexes with non-ionic surfactants to obtain washed complexes; 4) adding NH4HCO3 to dissolve the washed complex, and then digesting and terminating; 5) Desalting, vacuum concentration and mass spectrometry injection; 6) Perform detection using mass spectrometry and output the results.

2. The detection method according to claim 1, characterized in that: The sample is a CSF, blood or plasma sample; and / or The sample diluent in step 1) comprises: Tris-HCl, NaCl, EDTA, protease inhibitors and phosphatase inhibitors; and / or The sample diluent in step 1) further comprises NP40 and / or Tween 20; and / or The sample diluent in step 1) comprises: 20-80 mM Tris-HCl, 30-80 mM NaCl, 1-10 mM EDTA, and 0.02%-0.2% by mass of protease inhibitors and 0.02%-0.2% by mass of phosphatase inhibitors; and / or The sample diluent in step 1) further comprises NP40 lysate and / or Tween 20 at a mass fraction of 0.1%-1%.

3. The detection method according to claim 1, characterized in that: Step 2) includes: adding the nanomagnetic microsphere-p-Tau217 antibody complex to solution A, incubating with rotation at room temperature for at least 2 hours, passing through a magnetic rack to obtain a purified immune-enriched complex.

4. The detection method according to claim 1, characterized in that: Step 3) comprises: washing the immuno-enriched complex at least three times with a PBS solution containing 0.1% to 0.5% NP40 by mass.

5. The detection method according to claim 1, characterized in that: Step 4) includes: adding 20-200 mM NH4HCO3 to dissolve the washed complex, adding trypsin to digest for at least 8 hours, and adding 10% by mass formic acid aqueous solution to terminate the digestion.

6. The detection method according to claim 1, characterized in that: The desalination process in step 5) includes: ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate; ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate; ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate; ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate; ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate; and / or The vacuum concentration and mass spectrometry injection process in step 5) includes: passing the desalted sample through a vacuum concentration centrifuge and drying; and / or The mass spectrometry sampling process in step 5) includes: re-dissolving the dried sample with a formic acid aqueous solution having a mass fraction of 0.1%, and injecting the sample after oscillation and centrifugation; the mass spectrometer is an orbital ion trap mass spectrometer.

7. The detection method according to claim 1, characterized in that: Adding isotopic peptides as shown in Seq No. 1 to the reconstituted sample before mass spectrometry injection; and / or Before mass spectrometry injection, add the isotope peptide stock solution shown in Seq No. 1 to the reconstituted sample, shake and mix for 1 minute, centrifuge for 30 seconds, place it in the mass spectrometer injection system, and perform signal acquisition and signal conversion by mass spectrometry.

8. The detection method according to claim 1, characterized in that: The following steps are involved: 1) Sample pretreatment: adding a sample diluent to the sample to obtain a solution A; the sample diluent comprises: 0.1%-1% NP40 lysate by mass, 0.1%-1% Tween 20 by mass, 20-80mM Tris-HCl, 30-80mM NaCl, 0.02%-0.2% protease inhibitor by mass, and 0.02%-0.2% phosphatase inhibitor by mass; the sample is a CSF, blood or plasma sample; 2) Immunoenrichment: Add the nanomagnetic microsphere-p-Tau 217 antibody complex to solution A, incubate with rotation at room temperature for at least 2 hours, and pass through a magnetic rack to obtain a purified immune-enriched complex; 3) Washing: Wash the immuno-enriched complexes at least three times with a PBS solution containing 0.1% to 0.5% NP40 by mass to obtain washed complexes; 4) adding 20-200 mM NH4HCO3 to dissolve the washed complex, adding trypsin to digest for at least 8 h, and then adding 10% by mass formic acid aqueous solution to terminate the digestion; 5) Desalination: ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate; ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate; ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate; ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate; ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate; 6) Dry the desalted sample using a vacuum concentrator centrifuge, re-dissolve the dried sample in 0.1% formic acid water, shake and centrifuge, and then inject; 7) Perform detection by mass spectrometry and output the results; add the isotope peptide segment shown in SeqNo.1 during orbital ion trap mass spectrometry injection.

9. A detection kit for p-Tau 217 protein or a fragment thereof, characterized in that: include: 1) Pretreatment module: at least including sample diluent, the sample diluent including: NP40 lysate with a mass fraction of 0.1%-1%, Tween 20 with a mass fraction of 0.1%-1%, Tris-HCl with a concentration of 20-80mM, NaCl with a concentration of 30-80mM, protease inhibitor with a mass fraction of 0.02%-0.2%, and phosphatase inhibitor with a mass fraction of 0.02%-0.2%; 2) Immunoenrichment module: at least including nanomagnetic microsphere-p-Tau 217 antibody complex; 3) Cleaning and re-dissolving module: at least including PBS solution with a mass fraction of 0.1%-0.5% NP40 and NH4HCO3 solution with a concentration of 20-200mM; 4) Desalination module: at least including methanol, 80% by mass acetonitrile aqueous solution, 1% by mass formic acid aqueous solution, and 80% by mass acetonitrile aqueous solution; 5) Drying and injection module: at least including 0.1% by mass formic acid water and the isotopic peptide segment shown in Seq No.

1.

10. Use of the kit according to claim 9 in early diagnosis of Alzheimer's disease.

Citation Information

Patent Citations

  • Methods for measuring concentrations of biomolecules in biofluids

    CN110869039A

  • Homogeneous immunodetection kit for Alzheimer's disease

    CN115078736A

  • Blood-based assays for detecting tauopathies or amyloid formative diseases

    CN116348769A

  • Application of anti-DNA antibody in preparation of kit for early diagnosis of Alzheimer's disease

    CN117310175A

  • Test kit for testing biomarkers of alzheimer disease and the method thereof

    US20240085436A1